Health
Phase 3 trials show AstraZeneca COVID vaccine has up to 90% efficacy – CIDRAP
The peer-reviewed data mirror unpublished results noted last month by the researchers, with up to 90% protection.
The first full peer-reviewed results of phase 3 trials of the COVID-19 vaccine developed by AstraZeneca and Oxford University show that it is safe and up to 90% effective in preventing infection, supporting regulatory submissions for emergency use.
The interim analysis, published today in The Lancet, identified no severe coronavirus disease or hospitalizations in pooled results from the 11,636 adults vaccinated in the United Kingdom and Brazil. Of the 11,636 adults, 131 (1.1%) had symptomatic COVID-19…
-
Noosa News22 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
General16 hours agoLabor to pledge $2.3 billion to subsidise home batteries
-
General22 hours ago307,000 Voices | The Spectator Australia
-
General22 hours agoLive and dead animals seized from Kyneton business after investigation